首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 171 毫秒
1.
2.
探索用PGenesil-1(Pg)构建的靶向乙型肝炎病毒表面抗原(HBsAg)基因的shRNA表达载体PGenesil-1-HBs(简称Pgs),对体外培养HepG2.2.15细胞中的HBV基因及其抗原表达的抑制作用.设计、合成靶向HBV S区的3对DNA序列,分别插入PGenesil-1中构建3个siRNA表达载体Pgs1、Pgs2、Pgs3,经限制性内切酶,DNA序列测定等技术鉴定确认.筛选并确定最佳细胞接种量及重组质粒转染量后,分别或按不同组合转染HepG-2.2.15细胞,48 h后采用半定量RT-PCR检测HBVsmRNA转录水平,免疫细胞化学技术检测HBsAg表达水平,MEIA分别检测细胞裂解液和培养上清中HBsAg和HBeAg的表达水平.结果表明,HBV真核表达载体Pgs1、Pgs2、Pgs3均能不同程度地抑制HepG2.2.15细胞中的HBsAg、HBeAg合成和HBs-mRNA转录.成功构建的HBV真核表达载体Pgs1、Pgs2、Pgs3,其中PgS3能显著抑制HBsAg表达(P<0.01).多种表达载体联合对抗原表达的抑制作用效率不同.  相似文献   

3.
研究磷脂爬行酶1(Phospholipid scramblase 1,PLSCR1)对干扰素抑制HBV作用的影响。设计合成PLSCR1特异性小干扰RNA(siRNA),以完全随机序列的阴性小干扰(NCsiRNA)作为对照,转染HepG2细胞,于转染48h后分别检测PLSCR1mRNA和蛋白水平表达量的变化,筛选出对PLSCR1具有沉默作用的siRNA;将HepG2细胞分为正常对照组和干扰素处理组,将1.3倍乙型肝炎病毒(HBV)全基因真核细胞表达载体HBV1.3质粒分别与PLSCR1siRNA或NCsiRNA共同转染HepG2细胞或干扰素处理的HepG2细胞,转染48h后检测各组细胞中PLSCR1mRNA表达量及培养液上清中HBsAg表达水平。PLSCR1特异性小干扰RNA siRNA911转染后能够显著抑制HepG2细胞中PLSCR1基因在mRNA和蛋白水平的表达;与HepG2细胞对照组比较,干扰素处理组细胞转染HBV1.3质粒、NCsiRNA+HBV1.3质粒后,细胞培养液中HBsAg表达水平均显著降低(P0.05);而PLSCR1siRNA与HBV1.3共转染IFN处理的HepG2细胞组与共转染HepG2细胞组相比较,细胞培养液中HBsAg的表达水平没有显著差异。提示抑制PLSCR1的siRNA可抑制干扰素的抗HBV活性,提示PLSCR1在干扰素抑制HBV复制中具有重要作用。  相似文献   

4.
应用微阵列技术筛选PS1TP1基因转染细胞差异表达基因   总被引:2,自引:0,他引:2  
纪冬  成军  郭江  刘妍  王琳  郭风劲 《中国病毒学》2005,20(3):239-242
阐明乙型肝炎病毒(HBV)前-S1蛋白反式激活蛋白1(PS1TP1)的表达对于肝细胞的基因表达谱的影响.应用基因芯片技术对于pcDNA3.1(-)和pcDNA3.1(-)-PS1TP1分别转染的HepG2细胞的基因表达谱进行分析.以肝癌细胞系HepG2基因作为模板,应用聚合酶链反应(PCR)技术扩增PS1TP1基因片段,以常规的分子生物学技术构建表达载体pcDNA3.1(-)-PS1TP1.以脂质体技术转染肝母细胞瘤细胞系HepG2,提取总RNA,逆转录为cDNA,与转染空白表达载体pcDNA3.1(-)的HepG2细胞进行DNA芯片分析并比较.在4096个基因表达谱的筛选中,发现有8个基因表达水平显著上调,14个基因表达水平显著下调.PS1TP1基因的表达对于肝细胞基因表达谱有显著影响.DNA芯片技术是分析反式调节靶基因的有效技术途径.  相似文献   

5.
阐明乙型肝炎病毒(HBV)前S1蛋白反式激活蛋白1(PS1TP1)的表达对于肝细胞的基因表达谱的影响。应用基因芯片技术对于pcDNA3.1()和pcDNA3.1()PS1TP1分别转染的HepG2细胞的基因表达谱进行分析。以肝癌细胞系HepG2基因作为模板,应用聚合酶链反应(PCR)技术扩增PS1TP1基因片段,以常规的分子生物学技术构建表达载体pcDNA3.1()PS1TP1。以脂质体技术转染肝母细胞瘤细胞系HepG2,提取总RNA,逆转录为cDNA,与转染空白表达载体pcDNA3.1()的HepG2细胞进行DNA芯片分析并比较。在4096个基因表达谱的筛选中,发现有8个基因表达水平显著上调,14个基因表达水平显著下调。PS1TP1基因的表达对于肝细胞基因表达谱有显著影响。DNA芯片技术是分析反式调节靶基因的有效技术途径。  相似文献   

6.
长非编码RNAs(long noncoding RNAs,lncRNAs)是一类长度大于200 nt、不能编码蛋白质的RNA分子,可通过AMPK、胰岛素受体等多种信号通路,调节细胞糖脂代谢。本研究发现,HepG2细胞中一条未报道的长链非编码RNA,命名为lnc-RLM(lnc-regulate lipid metabolism)。通过敲低HepG2细胞中lnc RLM,检测细胞中甘油三脂含量及脂质代谢相关调节因子表达量。结果显示,实验组较对照组甘油三酯含量显著升高(P<0.05);AMPK磷酸化水平显著下调,脂质合成相关因子SREBP 1c和FAS表达量上调;同时,细胞中乙酰辅酶A羧化酶(ACC)活性较对照组显著上调(P<0.05)。在lnc RLM敲低的HepG2细胞中,利用AMPK激动剂(A-769662)作用细胞24 h,结果显示,降低的AMPK磷酸化水平并不会因AMPK激动剂的作用而显著升高。本研究结果说明,HepG2细胞中敲低lnc-RLM表达量,可通过影响AMPK磷酸化水平,调节HepG2细胞中脂质沉积。这为今后研究AMPK活性调节提供新的可能,也为代谢性疾病的治疗提供了新思路。  相似文献   

7.
目的:研究体内、体外乙型肝炎病毒(hepatitis B virus,HBV)复制水平与肝细胞内质网应激(endoplasmic reticulum stress,ER stress)反应基因表达的相关性。方法:选择7例慢性HBV感染者作体内研究,用液氮冷冻保存肝脏穿刺活检组织,检测肝功能并提取m RNA;体外研究分三组,转染组(HepG2.2.15)为HBV基因转染人肝癌细胞株,对照组(HepG2)为人肝癌细胞株,干预组(3TC)为50μg/m L拉米夫定作用于HBV基因转染人肝癌细胞。分别培养2天、4天、6天后收集细胞提取m RNA。HBV DNA载量的测定用实时定量聚合酶链反应(PCR);活化转录因子4 (ATF4)、转录因子C/EBP同源蛋白(CHOP)、活化转录因子6(ATF6)、X盒结合蛋白1(XBP1)及葡萄糖调节蛋白78(GRP78)的m RNA表达,用SYBR Green荧光定量逆转录聚合酶链反应(SYBR Green RT-PCR)检测,以β-actin为内参照;GRP78的表达用蛋白免疫印迹法(WB)检测。结果:体内研究结果表明:XBP1、GRP78、CHOP及ATF6基因表达水平与病毒载量、炎症程度及肝组织纤维化程度无显著相关性(P0.05);ATF6与GRP78基因表达水平和HBV DNA水平呈显著正相关(P0.05)。体外研究结果表明:干预组细胞培养2天至6天HBV DNA水平下降,CHOP、GRP78、ATF6及XBP1基因表达水平在三组之间差异无统计学意义(P0.05);WB结果表明,转染组细胞GRP78的表达培养4天与6天相比差异无统计学意义(P0.05),干预组培养6天后与转染组比较差异无统计学意义(P0.05)。结论:研究结果提示体内HBV复制水平与肝细胞ER stress反应显著相关,而肝脏炎症程度及肝脏纤维化程度等与ER stress反应无明显相关性;体外三组细胞之间ER stress基因的表达无显著差异(P0.05)。  相似文献   

8.
长非编码RNAs(long noncoding RNAs,lncRNAs)是一类长度大于200 nt、不能编码蛋白质的RNA分子,可通过AMPK、胰岛素受体等多种信号通路,调节细胞糖脂代谢。本研究发现,HepG2细胞中一条未报道的长链非编码RNA,命名为lnc-RLM(lnc-regulate lipid metabolism)。通过敲低HepG2细胞中lnc-RLM,检测细胞中甘油三脂含量及脂质代谢相关调节因子表达量。结果显示,实验组较对照组甘油三酯含量显著升高(P0.05);AMPK磷酸化水平显著下调,脂质合成相关因子SREBP 1c和FAS表达量上调;同时,细胞中乙酰辅酶A羧化酶(ACC)活性较对照组显著上调(P0.05)。在lnc-RLM敲低的HepG2细胞中,利用AMPK激动剂(A-769662)作用细胞24 h,结果显示,降低的AMPK磷酸化水平并不会因AMPK激动剂的作用而显著升高。本研究结果说明,HepG2细胞中敲低lnc-RLM表达量,可通过影响AMPK磷酸化水平,调节HepG2细胞中脂质沉积。这为今后研究AMPK活性调节提供新的可能,也为代谢性疾病的治疗提供了新思路。  相似文献   

9.
为研究NIRF(Np95/ICBP-90 like RING finger protein)对乙型肝炎病毒(hepatitis B virus,HBV)的复制以及与乙型肝炎病毒共价环状闭合DNA(HBV cccDNA)结合的组蛋白H3乙酰化的影响,采用脂质体转染将pGEM-HBV1.3+pFLAG、pGEM-HBV1.3+pFLAG-NIRF、pGEM-HBV1.3质粒分别转入HepG2细胞,Western blot检测NIRF蛋白的表达,用ELISA结合RT-PCR检测HBsAg、HBeAg以及HBV cccDNA的量并同时说明HBV在细胞内是完成完整复制表达的,采用染色质免疫共沉淀(ChIP)的方法检测与HBV cccDNA结合的组蛋白H3以及H3乙酰化水平的动态变化。结果显示,NIRF蛋白下调HBV标志物HBeAg、HBsAg的分泌以及HBV cccDNA的表达,表明其对HBV复制具有抑制作用;组蛋白H3及乙酰化的组蛋白H3都与HBV cccDNA的动态变化水平呈现相似的平行性,而NIRF蛋白也明显抑制组蛋白H3的表达水平和乙酰化水平。结论证实NIRF不仅能抑制HBV在肝癌细胞中的复制,而且能下调与HBV cccDNA结合的组蛋白H3和乙酰化组蛋白H3的表达。期待NIRF能为后续的HBV致病机理、HBV复制表观遗传学水平研究及有效抗病毒药物的研究与开发提供理论上的支持与帮助。  相似文献   

10.
目的:通过对比不同来源的人肝癌细胞系HepG2和原代大鼠肝细胞在体外降脂药物评价中药效反应,指导两种肝细胞在体外降脂药物评价中的实际应用。方法:用游离脂肪酸(油酸/棕榈酸,2:1)诱导HepG2细胞、原代大鼠肝细胞脂肪变性,并用100μmol·L-1苯扎贝特干预,检测细胞内甘油三酯(TG)、总胆固醇(TC)、活性氧(ROS)含量,细胞内脂滴数目、并检测细胞上清液中丙二醛(MDA)含量和超氧化物歧化酶(SOD)活性。结果:FFA刺激使HepG2细胞和原代大鼠肝细胞脂质沉积(TG、脂滴)和氧化应激(ROS、MDA、SOD)水平上升。苯扎贝特对HepG2细胞1 mmol·L-1FFA造模组和原代大鼠肝细胞0.5 mmol·L-1FFA造模组脂质沉积和氧化应激水平改善显著;而HepG2细胞0.5 mmol·L-1FFA造模组和原代大鼠肝细胞1 mmol·L-1FFA造模组脂质沉积和氧化应激水平在苯扎贝特干预后变化不明显。结论:在相同FFA造模浓度,原代大鼠肝细胞病理特征变化更为明显;苯扎贝特对两种肝细胞在脂质沉积和氧化应激水平的作用也不完全相同。因而HepG2细胞和原代大鼠肝细胞在体外降脂药物评价中药效反应是不完全相同的。  相似文献   

11.
HepG2.2.15 cell is a widely used cell model for studying HBV (hepatitis B virus) in vitro. In these cells, the HBV genome is integrated in several sites of HepG2 cellular DNA. These multiple copies may have some influence on the cellular processes. We constructed a new plasmid, pSEH-Flag-HBV, and transfected it into HepG2 cells, and then screened it with hygromycin. We then used ELISA, PCR, and RT-PCR to detect the expression of HBV in these cell lines. A cell line that stably expressed hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) was established. Using Southern blotting analysis, we found that the HBV genome was integrated as a single copy in the cellular DNA. This cell line will be a useful alternative model for HBV studies.  相似文献   

12.
Hepatitis B virus (HBV) infection is a prevalent infectious disease with serious outcomes like chronic and acute hepatitis, cirrhosis, and hepatocellular carcinoma. However, the metabolic alteration by HBV is rarely taken into consideration. With the high prevalence of alcohol consumption and chronic HBV infection, their overlap is assumed to be an increasing latent hazard; although the extent has not been calculated. Moreover, the impact of chronic alcohol consumption combined with HBV on cholesterol metabolism is unknown. Six-week-old male FVB/Ncrl mice were hydrodynamically injected with a pGEM-4Z-1.3HBV vector and then fed an ethanol diet for 6 weeks. Serum biomarkers and liver histology, liver cholesterol levels, and cholesterol metabolism-related molecules were measured. In vitro assays with HBx, hepatitis B surface (HBs), or hepatitis B core (HBc) protein expression in HepG2 cells costimulated with ethanol were conducted to assess the cholesterol metabolism. HBV expression synergistically increased cholesterol deposition in the setting of alcoholic fatty liver. The increase of intrahepatic cholesterol was due to metabolic alteration in cholesterol metabolism, including increased cholesterol synthesis, decreased cholesterol degradation, and impaired cholesterol uptake. Overexpression of HBV component HBc, but not HBs or HBx, selectively promoted the hepatocellular cholesterol level.  相似文献   

13.
应用ELISA和PCR法检测502例乙肝病人血清,401例HBsAg阳性血清中,有114例(28.4%)抗-HCV和HCVRNA双项阳性,25例(6.2%)HCVRNA单项阳性;21例(5.2%)抗-HCV单项阳性。将HBsAg乙肝病人分成HBVDNA,HBeAg阳性组和HBVDNA,HBeAg阴性组。前者抗-HCV阳性率为11.6%~20.5%,HCVRNA阳性率为16.2%~20.5%。后者抗-HCV阳性率为20.2%~55.6%,HCVRNA阳性率为23%~60.3%。结果说明长期携带HBV者和慢性乙肝病人均可重叠HCV感染。HBVDNA阳性组抗-HCV和HCVRNA阳性率明显高于HBVDNA阳性组  相似文献   

14.
Hepatitis B virus (HBV) infection is a worldwide health problem and may develop to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. To investigate the global proteome responses of liver‐derived cells to HBV infection and IFNα treatment, 2‐DE and MS‐based analysis were performed to compare the proteome changes between HBV stably transfected cell line HepG2.2.15 and its parental cell line HepG2, as well as HepG2.2.15 before and after IFNα treatment (5000 IU/mL for 72 h). Compared to HepG2, 12 of 18 down‐regulated and 27 of 32 up‐regulated proteins were identified in HepG2.2.15. After IFNα treatment, 6 of 7 down‐regulated and 11 of 14 up‐regulated proteins were identified. Differentially expressed proteins caused by HBV infection were involved with cytoskeletal matrix, heat shock stress, kinases/signal transduction, protease/proteasome components, etc. Prohibitin showed a dose‐dependent up‐regulation during IFNα treatment and might play a potent role in anti‐HBV activities of IFNα by enhancing the crossbinding p53 expression to achieve the apoptosis of HBV infected liver cells. Down‐regulation of interferon‐stimulated gene 15 (ISG15) in HepG2.2.15 and recovery by IFNα suggested its relationship with IFNα's anti‐HBV effect.  相似文献   

15.
Antiviral therapy of chronic hepatitis B remains a major clinical problem worldwide. Like lamivudine, nucleoside analogs have become the focus of investigation of anti-hepatitis B virus (anti-HBV) drugs. Here, β-LPA is a novel 2,6-diaminopurine analog found to possess potent anti-HBV activity. In HepG2.2.15 cell line, β-LPA had a 50% effective concentration (EC50) of 0.01 μM against HBV, as determined by analysis of secreted and intracellular episomal HBV DNA. Levels of HBV surface antigen (HBsAg) and e antigen (HBeAg) in drug-treated cultures revealed that β-LPA had no significant inhibitory effects on HBsAg and HBeAg. β-LPA didn’t show any cytotoxicity up to 0.4 μM with a 50% cytotoxic concentration (CC50) of 50 μM. Furthermore, treatment with β-LPA resulted in no apparent inhibitory effects on mitochondrial DNA content. Considering the potent inhibition of HBV DNA synthesis and no obvious toxicity of β-LPA, this compound should be further explored for development as an anti-HBV drug.  相似文献   

16.
深入研究HBV复制机理,筛选参与HBV复制的基因,可能为开发抗乙肝病毒新药提供新 的靶点.本文拟建立一种筛选HBV复制相关基因的方法: RNAi文库感染HepG2.2.15细胞后,利用免疫磁珠收集HBsAg表达降低的细胞,提取DNA,PCR扩增siRNA编码序列,将PCR产物克隆入T-easy载体,随机挑选克隆测序,发现DDB1基因可能参与HBV复制.本试验建立了一种筛选HBV复制相关基因的方法,为大规模全基因组筛选参与HBV复制的基因奠定了基础.  相似文献   

17.
Hepatitis B virus surface antigen(HBsAg),a specific antigen on the membrane of Hepatitis B virus (HBV)-infected cells,provides a perfect target for therapeutic drugs.The development of reagents with high affinity and specificity to the HBsAg is of great significance to the early-stage diagnosis and treatment of HBV infection.Herein,we report the selection of RNA aptamers that can specifically bind to HBsAg protein and HBsAg-positive hepatocytes.One high affinity aptamer,HBs-A22,was isolated from an initial 115 mer library of ~1.1×10 15 random-sequence RNA molecules using the SELEX procedure.The selected aptamer HBs-A22 bound specifically to hepatoma cell line HepG2.2.15 that expresses HBsAg but did not bind to HBsAg-devoid HepG2 cells.This is the first reported RNA aptamer which could bind to a HBV specific antigen.This newly isolated aptamer could be modified to deliver imaging,diagnostic,and therapeutic agents targeted at HBV-infected cells.  相似文献   

18.
We investigated the effects of stearic acid (saturated), oleic acid (monounsaturated), linoleic acid (n-6 polyunsaturated), and alpha-linolenic acid (n-3 polyunsaturated) on lipid metabolism in a hepatocyte-derived cell line, HepG2. HepG2 cells were cultured in medium supplemented with either stearic acid (0.1% w/v), oleic acid (0.1% v/v), linoleic acid (0.1% v/v), or alpha-linolenic acid (0.1% v/v). After 24 h, expression of lipid metabolism-associated genes was evaluated by real-time PCR. Alpha-linolenic acid showed a suppressive effect on the hepatic fatty acid de novo synthesis and fatty acid oxidation pathways, while linoleic acid also showed a tendency to suppress these pathways although the effect was weaker. Moreover, alpha-linolenic acid enhanced the expression of enzymes associated with reactive oxygen species (ROS) elimination. In contrast, oleic acid tended to promote fatty acid synthesis and oxidation. In conclusion, alpha-linolenic acid and linoleic acid may be expected to ameliorate hepatic steatosis by downregulating fatty acid de novo synthesis and fatty acid oxidation, and by upregulating ROS elimination enzymes. Oleic acid had no distinct effects for improving steatosis or oxidative stress.  相似文献   

19.
Human HepG2 cells were exposed to six TiO2 nanomaterials (with dry primary particle sizes ranging from 22 to 214 nm, either 0.3, 3, or 30 μg/mL) for 3 days. Some of these canonical pathways changed by nano‐TiO2 in vitro treatments have been already reported in the literature, such as NRF2‐mediated stress response, fatty acid metabolism, cell cycle and apoptosis, immune response, cholesterol biosynthesis, and glycolysis. But this genomic study also revealed some novel effects such as protein synthesis, protein ubiquitination, hepatic fibrosis, and cancer‐related signaling pathways. More importantly, this genomic analysis of nano‐TiO2 treated HepG2 cells linked some of the in vitro canonical pathways to in vivo adverse outcomes: NRF2‐mediated response pathways to oxidative stress, acute phase response to inflammation, cholesterol biosynthesis to steroid hormones alteration, fatty acid metabolism changes to lipid homeostasis alteration, G2/M cell checkpoint regulation to apoptosis, and hepatic fibrosis/stellate cell activation to liver fibrosis.  相似文献   

20.
Previous studies in our laboratory strongly suggested that fibronectin was upregulated by hepatitis B virus (HBV) in HepG2.2.15 cells. Report by Budkowska A also indicated that human liver fibronectin could bind HBV in a species-restricted manner. Therefore, it is reasonable to ask whether inhibiting fibronectin expression might have anti-HBV activity and whether fibronectin might be developed as a new potential cellular target for anti-HBV drugs. By using fibronectin antisense oligonucleotide (ASODN), fibronectin antibody, and Protocatechuic aldehyde (PA), we were able to show that HBV productions in HepG2.2.15 cell culture were reduced in a dose-dependent manner by fibronectin inhibition. In addition, we found that treatment with ASODNs, fibronectin antibody, and PA did not affect HepG2.2.15 cell viability. Furthermore, we observed that fibronectin inhibition sensitized HBV to anti-HBV drugs. In summary, this study demonstrates that fibronectin is essential for HBV propagation and also provides some evidences for the potential of fibronectin as a new cellular target for HBV infection therapy.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号